WO2000068380A3 - Extracellular matrix and adhesion-associated proteins - Google Patents

Extracellular matrix and adhesion-associated proteins Download PDF

Info

Publication number
WO2000068380A3
WO2000068380A3 PCT/US2000/012811 US0012811W WO0068380A3 WO 2000068380 A3 WO2000068380 A3 WO 2000068380A3 US 0012811 W US0012811 W US 0012811W WO 0068380 A3 WO0068380 A3 WO 0068380A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
subject
idem
partially
pct
Prior art date
Application number
PCT/US2000/012811
Other languages
French (fr)
Other versions
WO2000068380A2 (en
Inventor
Olga Bandman
Jennifer L Hillman
Y Tom Tang
Preeti Lal
Henry Yue
Mariah R Baughn
Dyung Aina M Lu
Yalda Azimzai
Original Assignee
Incyte Genomics Inc
Olga Bandman
Jennifer L Hillman
Y Tom Tang
Preeti Lal
Henry Yue
Mariah R Baughn
Dyung Aina M Lu
Yalda Azimzai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Olga Bandman, Jennifer L Hillman, Y Tom Tang, Preeti Lal, Henry Yue, Mariah R Baughn, Dyung Aina M Lu, Yalda Azimzai filed Critical Incyte Genomics Inc
Priority to JP2000616346A priority Critical patent/JP2002543785A/en
Priority to AU51298/00A priority patent/AU5129800A/en
Priority to EP00935907A priority patent/EP1177296A2/en
Priority to CA002372815A priority patent/CA2372815A1/en
Publication of WO2000068380A2 publication Critical patent/WO2000068380A2/en
Publication of WO2000068380A3 publication Critical patent/WO2000068380A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides human extracellular matrix and adhesion-associated proteins (EXMAD) and polynucleotides which identify and encode EXMAD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of EXMAD.

Description

Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
P,X DATABASE EMBL [Onl i ne] 1-17,20,
Accession number AF151838, 23
1 June 1999 (1999-06-01)
XP002146659 the whole document
& LAI C.-H. ET AL.: "Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics"
GENOME RESEARCH, vol. 10, no. 5, May 2000 (2000-05), pages
703-713,
Form PCT/ISA 210 (continuation of second sheet) (July 1992) page 2 of 2 Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons-
1 I xJ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2 |~X~j Claims Nos • 18 » 19 > 21 , 22 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically see FURTHER INFORMATION sheet PCT/ISA/210
I I Claims Nos.- because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 64(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. I I As all required additional search fees were timely paid by the applicant, this International Search Report covers all
I ' coαπ-hahlfi claims
2. I I As all searchable claims could be searched without effort justifying an additional fee, this Authoπty did not invite payment of any additional fee
3. I I As only some of the required additional search fees were timely paid by the applicant, this International Search Report i 1 m couvflerars o onnllvy t thhoossee c cllaaiimmss f foorr wwhhiicchh ffeeeess w weerree p Daaiidd., S sDpeecciiffiiccaallllvy c cllaaiimmss N Nooss. •
4 l y l No required additional search fees were timely paid by the applicant. Consequently, this International Search Report i ^^ restricted to the invention first mentioned in the claims; it is covered by claims Nos..
1-23 (partially)
Remark on Protest [ j The additional search fees were accompanied by the applicant's protest.
I I No protest accompanied the payment of additional search fees.
Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998) International Application No. PCT/US 00 /12811
FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210
Continuation of Box 1.2 Claims Nos.: 18, 19, 21, 22
Present claims 18, 19, 21 and 22, directed to agonists and antagonists relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not to be found, however, for any specific example of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for claims 18, 19, 21 and 22.
The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
International Application No. PCT/US 00/12811
FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210
This International Searching Authority found multiple (groups of) inventions in this international application, as follows:
1. Claims: 1-23 partially
Polypeptide comprising SEQ ID N0:1, variants and fragments thereof, antibody binding to it; polynudeotide of SEQ ID N0:26, variants thereof, cell and transgenic organism comprising the same; probes derived from the polynudeotide and use thereof in a diagnostic method; pharmaceutical composition comprising the polypeptide and its therapeutic use; use of the polypeptide in screening assays for agonists, antagonists and compounds capable of altering the expression of the polynu eotide; therapeutic use of the agonists and antagonists.
2. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:2 and 27
3. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:3 and 28
4. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:4 and 29
5. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:5 and 30
6. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:6 and 31
7. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:7 and 32
8. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:8 and 33
9. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:9 and 34 page 1 of 3 International Application No. PCT/US 00/12811
FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210
10. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:10 and 35
11. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:ll and 36
12. Claims : 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:12 and 37
13. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:13 and 38
14. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:14 and 39
15. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:15 and 40
16. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:16 and 41
17. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:17 and 42
18. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s:18 and 43
19. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:19 and 44
20. Claims: 1-23 partially
Idem as subject 1 for SEQ ID N0s :20 and 45 page 2 of 3 International Application No. PCT/US 00 /12811
FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210
21. Claims : 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:21 and 46
22. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s :22 and 47
23. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:23 and 48
24. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:24 and 49
25. Claims: 1-23 partial ly
Idem as subject 1 for SEQ ID N0s:25 and 50
page 3 of 3 Patent document Publication Patent family Publication cited in search report date member(s) date
WO 9900410 07-01-1999 US 5872234 A 16-02-1999 AU 8160898 A 19-01-1999 EP 0988318 A 29-03-2000
Form PCT/ISA/210 (patent family annex) (July 1992)
PCT/US2000/012811 1999-05-11 2000-05-10 Extracellular matrix and adhesion-associated proteins WO2000068380A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000616346A JP2002543785A (en) 1999-05-11 2000-05-10 Extracellular matrix and adhesion-related proteins
AU51298/00A AU5129800A (en) 1999-05-11 2000-05-10 Extracellular matrix and adhesion-associated proteins
EP00935907A EP1177296A2 (en) 1999-05-11 2000-05-10 Extracellular matrix and adhesion-associated proteins
CA002372815A CA2372815A1 (en) 1999-05-11 2000-05-10 Extracellular matrix and adhesion-associated proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13364399P 1999-05-11 1999-05-11
US60/133,643 1999-05-11
US15040999P 1999-08-23 1999-08-23
US60/150,409 1999-08-23

Publications (2)

Publication Number Publication Date
WO2000068380A2 WO2000068380A2 (en) 2000-11-16
WO2000068380A3 true WO2000068380A3 (en) 2001-04-19

Family

ID=26831550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012811 WO2000068380A2 (en) 1999-05-11 2000-05-10 Extracellular matrix and adhesion-associated proteins

Country Status (5)

Country Link
EP (1) EP1177296A2 (en)
JP (1) JP2002543785A (en)
AU (1) AU5129800A (en)
CA (1) CA2372815A1 (en)
WO (1) WO2000068380A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450402A1 (en) * 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
JP2003513668A (en) * 1999-11-12 2003-04-15 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 6 human secretory proteins
FR2804962B1 (en) * 2000-02-10 2005-02-25 Aventis Pharma Sa PARTNERS OF THE PTB1 DOMAIN OF FE65, PREPARATION AND USES
CA2399865C (en) * 2000-02-14 2011-10-25 Fuso Pharmaceutical Industries, Ltd. Novel scavenger receptor
DE10043227A1 (en) * 2000-09-01 2002-03-14 Develogen Ag Novel developmental gene
US7326678B2 (en) 2001-01-16 2008-02-05 Serono Genetics Institute S.A. GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereof
US6762293B2 (en) * 2001-06-29 2004-07-13 Erasmus University Rotterdam Diagnostics and therapeutics for autosomal dominant hemochromatosis
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
WO2003009864A1 (en) * 2001-07-23 2003-02-06 Genset S.A. Agonists and antagonists of disomet for the treatment of metabolic disorders
WO2003009861A1 (en) * 2001-07-24 2003-02-06 Genset S.A. Agonists and antagonists of metabolix in the treatment of metabolic disorders
WO2003009865A1 (en) * 2001-07-25 2003-02-06 Genset S.A. Agonists and antagonists of energen for use in the treatment of metabolic disorders
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
WO2003011325A1 (en) * 2001-07-27 2003-02-13 Genset S.A. Agonists and antagonists of moceptin for the treatment of metabolic disorders
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
EP1418934A1 (en) 2001-08-02 2004-05-19 Genset S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003011320A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of obesingen for the treatment of metabolic disorders
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
WO2003013579A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Lypergix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013580A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Tr xidatin agonists and antagonists treatment of metabolic disorders
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
WO2003013582A1 (en) * 2001-08-06 2003-02-20 Genset S.A. Genoxit agonists and antagonists for use in the treatment of metabolic disorders
AU2002328173A1 (en) * 2001-08-07 2003-02-24 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003013585A1 (en) * 2001-08-08 2003-02-20 Genset S.A. Mifaxin agonists and antagonists for use in the treatment of metabolic
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
AU2002339213A1 (en) * 2001-08-09 2003-02-24 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013583A1 (en) * 2001-08-10 2003-02-20 Genset S.A. Faxigen agonists and antagonists in the treatment of metabolic disorders
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
WO2003041730A1 (en) * 2001-11-16 2003-05-22 Genset S.A. Ditacin agonists and antagonists for use in the treatment of metabolic disorders
WO2003045421A1 (en) * 2001-11-28 2003-06-05 Genset S.A. Agonists and antagonists of ryzn for the treatment of metabolic disorders
WO2003045422A1 (en) * 2001-11-29 2003-06-05 Genset S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders
WO2003047614A1 (en) * 2001-12-05 2003-06-12 Genset S.A. Agonist and antagonists of redax for the treatment of metabolic disorders
AU2002339689A1 (en) * 2001-12-05 2003-06-17 Genset S.A. Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002339681A1 (en) * 2001-12-12 2003-06-23 Genset S.A. Agonists and antagonists of glucomin for the treatment of metabolic disorders
WO2003049756A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Glucomin agonists and antagonists for use in the treatment of metabolic disorders
WO2003049759A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002339682A1 (en) * 2001-12-13 2003-06-23 Genset S.A. Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2002339688A1 (en) * 2001-12-14 2003-06-30 Genset S.A. Glucoset agonists and antagonists for use in the treatment of metabolic disorders
AU2002339680A1 (en) * 2001-12-26 2003-07-15 Genset S.A. Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2003219167A1 (en) * 2002-03-19 2003-09-29 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
CA2480291A1 (en) * 2002-04-26 2003-11-06 Zymogenetics, Inc. Adipocyte complement related protein zacrp14
AU2003253677A1 (en) * 2002-06-11 2003-12-22 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
MXPA05012414A (en) * 2003-05-21 2006-02-13 Ares Trading Sa Tnf-like secreted protein.
GB0424497D0 (en) * 2004-11-05 2004-12-08 Univ Sheffield Anti-inflammatory agent
GB0424494D0 (en) * 2004-11-05 2004-12-08 Univ Sheffield Use
KR20120135405A (en) * 2010-03-04 2012-12-13 후소 야쿠힝 고교 가부시끼가이샤 Ischemic disorder-promoting polypeptide
JP2012021943A (en) * 2010-07-16 2012-02-02 National Cancer Center Method for inspecting uterine cancer, test drug for uterine cancer and antibody for uterine cancer antigen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000410A2 (en) * 1997-06-27 1999-01-07 Incyte Pharmaceuticals, Inc. Human extracellular matrix proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000410A2 (en) * 1997-06-27 1999-01-07 Incyte Pharmaceuticals, Inc. Human extracellular matrix proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 1 June 1999 (1999-06-01), XP002146659 *
DATABASE EMBL 14 October 1998 (1998-10-14), ROBERT STRAUSBERG: "qd66g12.x1 Soares_testis_NHT Homo sapiens cDNA clone", XP002146658 *
LAI C.-H. ET AL.: "Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics", GENOME RESEARCH, vol. 10, no. 5, May 2000 (2000-05-01), pages 703 - 713, XP002201533, DOI: doi:10.1101/gr.10.5.703 *

Also Published As

Publication number Publication date
JP2002543785A (en) 2002-12-24
EP1177296A2 (en) 2002-02-06
AU5129800A (en) 2000-11-21
WO2000068380A2 (en) 2000-11-16
CA2372815A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000068380A3 (en) Extracellular matrix and adhesion-associated proteins
Yamaguchi et al. Negative regulation of transforming growth factor-β by the proteoglycan decorin
Hollander et al. Mammalian GADD34, an apoptosis-and DNA damage-inducible gene
Tong et al. A mouse gene encoding an oocyte antigen associated with autoimmune premature ovarian failure
Doxsey et al. Pericentrin, a highly conserved centrosome protein involved in microtubule organization
Haeseleer et al. Molecular characterization of a third member of the guanylyl cyclase-activating protein subfamily
Galiegue et al. Cloning and characterization of PRAX-1: a new protein that specifically interacts with the peripheral benzodiazepine receptor
Johnston et al. Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC
US7994301B2 (en) Modulators of body weight, corresponding nucleic acids and proteins
Hsueh et al. Disulfide-linked head-to-head multimerization in the mechanism of ion channel clustering by PSD-95
Saudan et al. Ductus ejaculatorius peptide 99B (DUP99B), a novel Drosophila melanogaster sex‐peptide pheromone
Plager et al. A novel and highly divergent homolog of human eosinophil granule major basic protein
JP2000333671A (en) Cloned glutamic acid decarboxylase
GB2292382A (en) Obesity(OB) polypeptides
LOEBEL et al. Cloning, post-translational modifications, heterologous expression and ligand-binding of boar salivary lipocalin
Stathakis et al. Human postsynaptic density-95 (PSD95): location of the gene (DLG4) and possible function in nonneural as well as in neural tissues
JP3090682B2 (en) Polypeptide having thyrotropin receptor activity, nucleic acid encoding this receptor and polypeptide, and use of such peptide
US20140088024A1 (en) Vesiculins
US5635370A (en) DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
Stursberg et al. Cloning and characterization of mammalian SMC1 and SMC3 genes and proteins, components of the DNA recombination complexes RC-1
WO2004005475A2 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
Mattei et al. The gene encoding the large human neurofilament subunit (NF-H) maps to the q121–q131 region on human chromosome 22
DE69233685T2 (en) Cloned glutamic acid decarboxylase
Gardiner et al. Characterization of a small variable surface glycoprotein from Trypanosoma vivax
WO1999046376A1 (en) Receptor from the superfamily of tnt-receptors from the human lung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2372815

Country of ref document: CA

Ref country code: CA

Ref document number: 2372815

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616346

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000935907

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000935907

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10009557

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000935907

Country of ref document: EP